Temat: "HORMONE receptor positive breast cancer" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles.
Autorzy:: Fenton MA; Legorreta Cancer Center, Brown University, Providence, RI 02903, USA.; Lifespan Cancer Institute, Providence, RI 02903, USA.
Tarantino P; Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA.; Breast Oncology Program, Dana Farber Brigham Cancer Center, Boston, MA 02215, USA.; Harvard Medical School, Boston, MA 02215, USA.; Department of Oncology and Onco-Hematology, University of Milan, 20122 Milan, Italy.
Graff SL; Legorreta Cancer Center, Brown University, Providence, RI 02903, USA.; Lifespan Cancer Institute, Providence, RI 02903, USA.; Pokaż więcej
Źródło:: Current oncology (Toronto, Ont.) [Curr Oncol] 2023 Nov 29; Vol. 30 (12), pp. 10211-10223. Date of Electronic Publication: 2023 Nov 29.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Triple Negative Breast Neoplasms*
Immunoconjugates*/therapeutic use
Humans ; Ado-Trastuzumab Emtansine

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Modulation of JAK-STAT Signaling by LNK: A Forgotten Oncogenic Pathway in Hormone Receptor-Positive Breast Cancer.
Autorzy:: López-Mejía JA; Departamento de Biología Molecular y Biotecnología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City 03100, Mexico.
Mantilla-Ollarves JC; Departamento de Biología Molecular y Biotecnología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City 03100, Mexico.
Rocha-Zavaleta L; Departamento de Biología Molecular y Biotecnología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City 03100, Mexico.; Programa Institucional de Cáncer de Mama, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City 03100, Mexico.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2023 Sep 30; Vol. 24 (19). Date of Electronic Publication: 2023 Sep 30.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Signal Transduction*/physiology
Breast Neoplasms*
Humans ; Female ; Janus Kinases/metabolism ; Prolactin/metabolism ; Interleukin-6/metabolism ; STAT Transcription Factors/metabolism

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Thymoquinone, a Novel Multi-Strike Inhibitor of Pro-Tumorigenic Breast Cancer (BC) Markers: CALR, NLRP3 Pathway and sPD-L1 in PBMCs of HR+ and TNBC Patients.
Autorzy:: Elgohary S; Clinical Pharmacology and Pharmacogenomics Research Group, Department of Pharmacology and Toxicology, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo 11835, Egypt.
Eissa RA; Department of Surgery, Faculty of Medicine, Ain Shams University, Cairo 11591, Egypt.
El Tayebi HM; Clinical Pharmacology and Pharmacogenomics Research Group, Department of Pharmacology and Toxicology, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo 11835, Egypt.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2023 Sep 19; Vol. 24 (18). Date of Electronic Publication: 2023 Sep 19.
Typ publikacji:: Journal Article
MeSH Terms:: Triple Negative Breast Neoplasms*/drug therapy
Humans ; NLR Family, Pyrin Domain-Containing 3 Protein/genetics ; Calreticulin/genetics ; Leukocytes, Mononuclear ; Carcinogenesis

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Clinical Treatment Score Post-5 Years as a Tool for Risk Estimation of Late Recurrence in Thai Patients With Estrogen-Receptor-Positive, Early Breast Cancer: A Validation Study.
Autorzy:: Dejthevaporn T; Division of Medical Oncology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Patanayindee P; Division of Medical Oncology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.; Medical Oncology Unit, Department of Medicine, Faculty of Medicine, Thammasat University, Bangkok, Thailand.; Pokaż więcej
Źródło:: Breast cancer : basic and clinical research [Breast Cancer (Auckl)] 2023 Jul 31; Vol. 17, pp. 11782234231186869. Date of Electronic Publication: 2023 Jul 31 (Print Publication: 2023).
Typ publikacji:: Journal Article

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Endocrine therapy initiation and overall survival outcomes with omission of radiation therapy in older Medicare patients with early-stage hormone-receptor-positive breast cancer.
Autorzy:: Shen C; Department of Surgery, The Pennsylvania State University, College of Medicine, Hershey, Pennsylvania, USA.; Department of Public Health Sciences, The Pennsylvania State University, College of Medicine, Hershey, Pennsylvania, USA.; Penn State Cancer Institute, Hershey, Pennsylvania, USA.
Li N; Department of Economics and Finance, Salisbury University, Salisbury, Maryland, USA.
Zhou S; Department of Public Health Sciences, The Pennsylvania State University, College of Medicine, Hershey, Pennsylvania, USA.; Penn State Cancer Institute, Hershey, Pennsylvania, USA.
Stahl K; Department of Surgery, The Pennsylvania State University, College of Medicine, Hershey, Pennsylvania, USA.; Penn State Cancer Institute, Hershey, Pennsylvania, USA.
Dodge D; Department of Surgery, The Pennsylvania State University, College of Medicine, Hershey, Pennsylvania, USA.; Penn State Cancer Institute, Hershey, Pennsylvania, USA.
Zhao H; Department of Health Services Research, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.; Pokaż więcej
Źródło:: Cancer medicine [Cancer Med] 2023 Mar; Vol. 12 (6), pp. 6935-6944. Date of Electronic Publication: 2022 Nov 25.
Typ publikacji:: Journal Article
MeSH Terms:: Breast Neoplasms*/radiotherapy
Breast Neoplasms*/drug therapy
Aged ; Humans ; Female ; United States/epidemiology ; Aged, 80 and over ; Medicare ; Chemotherapy, Adjuvant ; Mastectomy, Segmental ; Probability

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: E3 Ubiquitin Ligase NEDD4 Affects Estrogen Receptor α Expression and the Prognosis of Patients with Hormone Receptor-Positive Breast Cancer.
Autorzy:: Natori Y; Department of Medical Oncology, Fukushima Medical University, Fukushima 960-1295, Japan.
Suga J; Department of Medical Oncology, Fukushima Medical University, Fukushima 960-1295, Japan.
Tokuda E; Department of Medical Oncology, Fukushima Medical University, Fukushima 960-1295, Japan.
Tachibana K; Department of Breast Surgery, Fukushima Medical University, Fukushima 960-1295, Japan.
Imai JI; Translational Research Center, Fukushima Medical University, Fukushima 960-1295, Japan.
Honma R; Nippon Gene Co., Ltd., Tokyo 101-0054, Japan.
Azami Y; Department of Medical Oncology, Fukushima Medical University, Fukushima 960-1295, Japan.
Noda M; Department of Breast Surgery, Fukushima Medical University, Fukushima 960-1295, Japan.
Sasaki E; Department of Medical Oncology, Fukushima Medical University, Fukushima 960-1295, Japan.
Watanabe S; Translational Research Center, Fukushima Medical University, Fukushima 960-1295, Japan.
Ohtake T; Department of Breast Surgery, Fukushima Medical University, Fukushima 960-1295, Japan.
Saji S; Department of Medical Oncology, Fukushima Medical University, Fukushima 960-1295, Japan.; Pokaż więcej
Źródło:: Cancers [Cancers (Basel)] 2023 Jan 16; Vol. 15 (2). Date of Electronic Publication: 2023 Jan 16.
Typ publikacji:: Journal Article

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests.
Autorzy:: Saponaro M; Department of Clinical Medicine and Surgery, University of Naples Federico II, 80100 Naples, Italy.
Annunziata L; Department of Clinical Medicine and Surgery, University of Naples Federico II, 80100 Naples, Italy.
Turla A; Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Medical Oncology, ASST Spedali Civili, 25100 Brescia, Italy.
Viganò I; Medical Oncology, Ospedale Valduce, 22100 Como, Italy.
De Laurentiis M; Department of Breast and Thoracic Oncology, National Cancer Institute, Fondazione G. Pascale, 80100 Naples, Italy.
Giuliano M; Department of Clinical Medicine and Surgery, University of Naples Federico II, 80100 Naples, Italy.; Interdepartmental Center of Clinical and Translational Sciences (CIRCET), Federico II University, 80100 Naples, Italy.
Del Mastro L; Department of Medical Oncology, IRCCS Ospedale Policlinico San Martino, 16100 Genova, Italy.
Montemurro F; Breast Unit, Istituto di Candiolo, FPO-IRCCS, 10127 Candiolo, Italy.
Puglisi F; CRO Aviano, National Cancer Institute, IRCCS, 33081 Aviano, Italy.; Department of Medicine, University of Udine, 33100 Udine, Italy.
De Angelis C; Department of Clinical Medicine and Surgery, University of Naples Federico II, 80100 Naples, Italy.; Interdepartmental Center of Clinical and Translational Sciences (CIRCET), Federico II University, 80100 Naples, Italy.
Buono G; Department of Breast and Thoracic Oncology, National Cancer Institute, Fondazione G. Pascale, 80100 Naples, Italy.
Schettini F; Medical Oncology Department, IDIBAPS, Hospital Clinic of Barcelona, 08000 Barcelona, Spain.; Faculty of Medicine and Health Sciences, University of Barcelona, 08000 Barcelona, Spain.
Arpino G; Department of Clinical Medicine and Surgery, University of Naples Federico II, 80100 Naples, Italy.; Interdepartmental Center of Clinical and Translational Sciences (CIRCET), Federico II University, 80100 Naples, Italy.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2022 Nov 06; Vol. 23 (21). Date of Electronic Publication: 2022 Nov 06.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Breast Neoplasms*/drug therapy
Breast Neoplasms*/genetics
Humans ; Female ; Tamoxifen/therapeutic use ; Antineoplastic Agents, Hormonal/therapeutic use ; Chemotherapy, Adjuvant ; Adjuvants, Pharmaceutic/therapeutic use ; Adjuvants, Immunologic/therapeutic use ; Genomics ; Neoplasm Recurrence, Local/genetics ; Neoplasm Recurrence, Local/drug therapy

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: The Role of the 21-Gene Recurrence Score Assay in Hormone Receptor-Positive, Node-Positive Breast Cancer: The Canadian Experience.
Autorzy:: Yordanova M; Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC J1K 2R1, Canada.
Hassan S; Faculty of Medicine, Université de Montréal, Montréal, QC H3C 3T5, Canada.; Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), l'Institut de Cancer de Montréal, Montréal, QC H2X 0A9, Canada.; Division of Surgical Oncology, Department of Surgery, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC H2X 0C1, Canada.; Pokaż więcej
Źródło:: Current oncology (Toronto, Ont.) [Curr Oncol] 2022 Mar 16; Vol. 29 (3), pp. 2008-2020. Date of Electronic Publication: 2022 Mar 16.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms:: Breast Neoplasms*/drug therapy
Breast Neoplasms*/genetics
Canada ; Female ; Genomics ; Humans ; Prognosis

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Combination of Abemaciclib following Eribulin Overcomes Palbociclib-Resistant Breast Cancer by Inhibiting the G2/M Cell Cycle Phase.
Autorzy:: Pandey K; Hematology and Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam 13488, Korea.; Department of Biomedical Science, The Graduate School, CHA University, Seongnam 13620, Korea.
Katuwal NB; Hematology and Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam 13488, Korea.; Department of Biomedical Science, The Graduate School, CHA University, Seongnam 13620, Korea.
Park N; Hematology and Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam 13488, Korea.
Hur J; Hematology and Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam 13488, Korea.; Department of Biomedical Science, The Graduate School, CHA University, Seongnam 13620, Korea.
Cho YB; Hematology and Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam 13488, Korea.
Kim SK; Department of Surgery, CHA Bundang Medical Center, CHA University, Seongnam 13620, Korea.
Lee SA; Department of Surgery, CHA Bundang Medical Center, CHA University, Seongnam 13620, Korea.
Kim I; Department of Surgery, CHA Bundang Medical Center, CHA University, Seongnam 13620, Korea.
Lee SR; Department of Urology, CHA Bundang Medical Center, CHA University, Seongnam 13620, Korea.
Moon YW; Hematology and Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam 13488, Korea.; Pokaż więcej
Źródło:: Cancers [Cancers (Basel)] 2022 Jan 01; Vol. 14 (1). Date of Electronic Publication: 2022 Jan 01.
Typ publikacji:: Journal Article

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: PI3Kinase Inhibition in Hormone Receptor-Positive Breast Cancer.
Autorzy:: Dhakal A; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14642, USA.
Acharya L; Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA.
O'Regan R; Department of Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA.
Gandhi S; Roswell Park Cancer Institute, Buffalo, NY 14203, USA.
Falkson C; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14642, USA.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2021 Nov 02; Vol. 22 (21). Date of Electronic Publication: 2021 Nov 02.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Breast Neoplasms/*drug therapy
Phosphatidylinositol 3-Kinases/*chemistry
Phosphoinositide-3 Kinase Inhibitors/*therapeutic use
Receptor, ErbB-2/*metabolism
Receptors, Estrogen/*metabolism
Receptors, Progesterone/*metabolism
Animals ; Breast Neoplasms/enzymology ; Breast Neoplasms/pathology ; Female ; Humans

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: Efficacy of Fulvestrant in Women with Hormone-Resistant Metastatic Breast Cancer (mBC): A Canadian Province Experience.
Autorzy:: Andrahennadi S; College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada.
Sami A; College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada.; Saskatoon Cancer Centre, University of Saskatchewan, 20 Campus Drive, Saskatoon, SK S7N4H4, Canada.
Haider K; College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada.; Saskatoon Cancer Centre, University of Saskatchewan, 20 Campus Drive, Saskatoon, SK S7N4H4, Canada.
Chalchal HI; College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada.; Allan Blair Cancer Centre, University of Saskatchewan, Regina, SK S4T7T1, Canada.
Le D; College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada.; Radiation Oncology, Saskatoon Cancer Centre, University of Saskatchewan, 20 Campus Drive, Saskatoon, SK S7N4H4, Canada.
Ahmed O; College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada.; Saskatoon Cancer Centre, University of Saskatchewan, 20 Campus Drive, Saskatoon, SK S7N4H4, Canada.
Manna M; College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada.; Saskatoon Cancer Centre, University of Saskatchewan, 20 Campus Drive, Saskatoon, SK S7N4H4, Canada.
El-Gayed A; College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada.; Radiation Oncology, Saskatoon Cancer Centre, University of Saskatchewan, 20 Campus Drive, Saskatoon, SK S7N4H4, Canada.
Wright P; College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada.; Radiation Oncology, Saskatoon Cancer Centre, University of Saskatchewan, 20 Campus Drive, Saskatoon, SK S7N4H4, Canada.
Ahmed S; College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada.; Saskatoon Cancer Centre, University of Saskatchewan, 20 Campus Drive, Saskatoon, SK S7N4H4, Canada.; Pokaż więcej
Źródło:: Cancers [Cancers (Basel)] 2021 Aug 19; Vol. 13 (16). Date of Electronic Publication: 2021 Aug 19.
Typ publikacji:: Journal Article

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: Reliability of Ki67 visual scoring app compared to eyeball estimate and digital image analysis and its prognostic significance in hormone receptor-positive breast cancer.
Autorzy:: Arun I; Department of Pathology, Tata Medical Center, Newtown, Kolkata, India.
Venkatesh S; Department of Pathology, Tata Medical Center, Newtown, Kolkata, India.
Ahmed R; Department of Breast Oncosurgery, Tata Medical Center, Newtown, Kolkata, India.
Agrawal SK; Department of Breast Oncosurgery, Tata Medical Center, Newtown, Kolkata, India.
Leung SCY; University of British Columbia, Vancouver, BC, Canada.; Pokaż więcej
Źródło:: APMIS : acta pathologica, microbiologica, et immunologica Scandinavica [APMIS] 2021 Aug; Vol. 129 (8), pp. 489-502. Date of Electronic Publication: 2021 Jun 24.
Typ publikacji:: Comparative Study; Journal Article
MeSH Terms:: Mobile Applications*
Breast Neoplasms/*diagnosis
Image Processing, Computer-Assisted/*methods
Ki-67 Antigen/*metabolism
Receptors, Estrogen/*metabolism
Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Breast Neoplasms/genetics ; Breast Neoplasms/metabolism ; Breast Neoplasms/pathology ; Eye ; Female ; Humans ; Immunohistochemistry ; Ki-67 Antigen/genetics ; Prognosis ; Receptor, ErbB-2/genetics ; Receptor, ErbB-2/metabolism ; Receptors, Estrogen/genetics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: Prediction of distant metastatic recurrence by tumor-infiltrating lymphocytes in hormone receptor-positive breast cancer.
Autorzy:: Takada K; Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.
Kashiwagi S; Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan. .
Asano Y; Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.
Goto W; Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.
Kouhashi R; Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.
Yabumoto A; Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.
Ishihara S; Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.
Morisaki T; Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.
Shibutani M; Department of Gastrointestinal Surgery, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.
Tanaka H; Department of Gastrointestinal Surgery, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.
Hirakawa K; Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.; Department of Gastrointestinal Surgery, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.
Ohira M; Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.; Department of Gastrointestinal Surgery, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.; Pokaż więcej
Źródło:: BMC women's health [BMC Womens Health] 2021 May 29; Vol. 21 (1), pp. 225. Date of Electronic Publication: 2021 May 29.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Lymphocytes, Tumor-Infiltrating*
Neoplasm Recurrence, Local*
Chemotherapy, Adjuvant ; Hormones ; Humans ; Prognosis ; Tumor Microenvironment

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer.
Autorzy:: Andrahennadi S; College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada.
Sami A; College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada.; Saskatoon Cancer Center, Saskatchewan Cancer Agency, University of Saskatchewan, 20 Campus Drive, Saskatoon, SK S7N 4H4, Canada.
Manna M; College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada.; Saskatoon Cancer Center, Saskatchewan Cancer Agency, University of Saskatchewan, 20 Campus Drive, Saskatoon, SK S7N 4H4, Canada.
Pauls M; College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada.; Saskatoon Cancer Center, Saskatchewan Cancer Agency, University of Saskatchewan, 20 Campus Drive, Saskatoon, SK S7N 4H4, Canada.
Ahmed S; College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada.; Saskatoon Cancer Center, Saskatchewan Cancer Agency, University of Saskatchewan, 20 Campus Drive, Saskatoon, SK S7N 4H4, Canada.; Pokaż więcej
Źródło:: Current oncology (Toronto, Ont.) [Curr Oncol] 2021 May 11; Vol. 28 (3), pp. 1803-1822. Date of Electronic Publication: 2021 May 11.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Breast Neoplasms*/drug therapy
Aromatase Inhibitors/therapeutic use ; Female ; Hormones ; Humans ; Phosphatidylinositol 3-Kinases ; Receptors, Estrogen

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence.
Autorzy:: Pandey K; Hematology and Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam 13488, Korea.; Department of Biomedical Science, CHA University, Seongnam 13488, Korea.
Park N; Hematology and Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam 13488, Korea.
Park KS; Department of Biomedical Science, CHA University, Seongnam 13488, Korea.
Hur J; Hematology and Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam 13488, Korea.; Department of Biomedical Science, CHA University, Seongnam 13488, Korea.
Cho YB; Hematology and Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam 13488, Korea.
Kang M; Hematology and Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam 13488, Korea.
An HJ; Department of Pathology, CHA Bundang Medical Center, CHA University, Seongnam 13488, Korea.
Kim S; Department of Pathology, CHA Bundang Medical Center, CHA University, Seongnam 13488, Korea.
Hwang S; Department of Biomedical Science, CHA University, Seongnam 13488, Korea.; Department of Pathology, CHA Bundang Medical Center, CHA University, Seongnam 13488, Korea.
Moon YW; Hematology and Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam 13488, Korea.; Pokaż więcej
Źródło:: Cancers [Cancers (Basel)] 2020 Nov 29; Vol. 12 (12). Date of Electronic Publication: 2020 Nov 29.
Typ publikacji:: Journal Article

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: Significance of age-associated quality of life in patients with stage IV breast cancer who underwent endocrine therapy in Japan.
Autorzy:: Takada K; Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.
Kashiwagi S; Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.
Asano Y; Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.
Goto W; Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.
Morisaki T; Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.
Takahashi K; Department of Pharmacology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.
Shibutani M; Department of Gastrointestinal Surgery, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.
Amano R; Department of Hepato-Biliary-Pancreatic Surgery, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.
Takashima T; Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.
Tomita S; Department of Pharmacology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.
Hirakawa K; Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.; Department of Gastrointestinal Surgery, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.
Ohira M; Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.; Department of Gastrointestinal Surgery, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.; Pokaż więcej
Źródło:: Oncology letters [Oncol Lett] 2020 Nov; Vol. 20 (5), pp. 180. Date of Electronic Publication: 2020 Aug 31.
Typ publikacji:: Journal Article

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 17.

Tytuł:: CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge.
Autorzy:: de Melo Gagliato D; Centro Oncológico Antonio Ermírio de Moraes, Beneficência Portuguesa de São Paulo, 01323001 São Paulo, Brazil.
C Buzaid A; Centro Oncológico Antonio Ermírio de Moraes, Beneficência Portuguesa de São Paulo, 01323001 São Paulo, Brazil.; Centro Oncológico Hospital Israelita Albert Eisntein, 05652900 São Paulo, Brazil.
Perez-Garcia JM; Baselga Institute of Oncology, Quiron University Hospital Barcelona, 08023 Barcelona, Spain.
Llombart A; Baselga Institute of Oncology, Quiron University Hospital Barcelona, 08023 Barcelona, Spain.
Cortes J; Ramon y Cajal University Hospital, 28034 Madrid, Spain.; Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain.; Pokaż więcej
Źródło:: Cancers [Cancers (Basel)] 2020 Sep 01; Vol. 12 (9). Date of Electronic Publication: 2020 Sep 01.
Typ publikacji:: Journal Article; Review

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 18.

Tytuł:: Using Phosphatidylinositol Phosphorylation as Markers for Hyperglycemic Related Breast Cancer.
Autorzy:: Devanathan N; Department of Biology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Jones S; Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Kaur G; Department of Chemistry, Indiana University Bloomington, IN 47405, USA.
Kimble-Hill AC; Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2020 Mar 27; Vol. 21 (7). Date of Electronic Publication: 2020 Mar 27.
Typ publikacji:: Journal Article
MeSH Terms:: Biomarkers, Tumor*
Breast Neoplasms/*metabolism
Hyperglycemia/*metabolism
Phosphatidylinositols/*metabolism
Breast/pathology ; Breast Neoplasms/complications ; Breast Neoplasms/pathology ; Cell Line, Tumor ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/metabolism ; Female ; Glucose/metabolism ; Humans ; Hyperglycemia/complications ; MCF-7 Cells ; Phosphorylation ; Phosphotransferases (Alcohol Group Acceptor) ; Receptor, ErbB-2/metabolism ; Receptor, Insulin ; Signal Transduction

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 19.

Tytuł:: Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer.
Autorzy:: Vernieri C; Fondazione Istituto FIRC di Oncologia Molecolare (IFOM), Via Adamello 16, 20133 Milan, Italy.; Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.
Prisciandaro M; Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.
Nichetti F; Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.
Lobefaro R; Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.
Peverelli G; Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.
Ligorio F; Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.
Zattarin E; Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.
Cona MS; ASST Fatebenefratelli Sacco - PO Luigi Sacco, Milan, Italy, Via G.B. Grassi 74, 20133 Milan, Italy.
Sepe P; Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.
Corti F; Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.
Manglaviti S; Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.
Brambilla M; Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.
Re B; SC Pharmacy, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.
Belfiore A; Department of Diagnostic Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.
Pruneri G; Department of Diagnostic Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, 20133 Milan, Italy.
Celio L; Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.
Mariani G; Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.
Bianchi GV; Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.
Rivoltini L; Unit of Immunotherapy of Human Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.
Capri G; Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.
de Braud F; Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, 20133 Milan, Italy.; Pokaż więcej
Źródło:: Cancers [Cancers (Basel)] 2020 Mar 06; Vol. 12 (3). Date of Electronic Publication: 2020 Mar 06.
Typ publikacji:: Journal Article

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 20.

Tytuł:: Aberrant fatty acid profile and FFAR4 signaling confer endocrine resistance in breast cancer.
Autorzy:: Chu X; Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Institutes for Translational Medicine, Soochow University, Changzhou, Jiangsu, China.; Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.
Zhou Q; Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Institutes for Translational Medicine, Soochow University, Changzhou, Jiangsu, China.
Xu Y; Department of Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine (SJTUSM), Shanghai, China.
Jiang J; Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Institutes for Translational Medicine, Soochow University, Changzhou, Jiangsu, China.
Li Q; Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Institutes for Translational Medicine, Soochow University, Changzhou, Jiangsu, China.
Zhou Q; Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.
Wu Q; Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.
Jin M; Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.
Wang H; Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Institutes for Translational Medicine, Soochow University, Changzhou, Jiangsu, China.
Gu Y; Department of Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine (SJTUSM), Shanghai, China.
Wang X; Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.
Wang B; Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.
He S; Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Institutes for Translational Medicine, Soochow University, Changzhou, Jiangsu, China.
He X; Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Institutes for Translational Medicine, Soochow University, Changzhou, Jiangsu, China.
Wu C; Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Institutes for Translational Medicine, Soochow University, Changzhou, Jiangsu, China. .
Zhang F; Department of Oncology, Suzhou Kowloon Hospital and Shanghai Ruijin Hospital, SJTUSM, Suzhou, Jiangsu, China. .
Zhang Y; Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Institutes for Translational Medicine, Soochow University, Changzhou, Jiangsu, China. .; Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China. .; Pokaż więcej
Źródło:: Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2019 Feb 22; Vol. 38 (1), pp. 100. Date of Electronic Publication: 2019 Feb 22.
Typ publikacji:: Journal Article
MeSH Terms:: Breast Neoplasms/*metabolism
Fatty Acids/*metabolism
Receptors, G-Protein-Coupled/*metabolism
Adult ; Aged ; Antineoplastic Agents, Hormonal/therapeutic use ; Breast Neoplasms/drug therapy ; Cell Line, Tumor ; Cohort Studies ; Drug Resistance, Neoplasm/drug effects ; Female ; Humans ; MCF-7 Cells ; Middle Aged ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/metabolism ; Prognosis ; RNA, Messenger/metabolism ; Receptors, Estrogen/metabolism ; Signal Transduction/physiology ; Tamoxifen/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""HORMONE receptor positive breast cancer"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język